Answers are grounded in this paper and cite their sources.
Comprehensive review highlights dendrimer-mediated therapy potential for improved stroke recovery, suggesting significant benefits.
Stroke is a leading cause of mortality and long-term disability worldwide, with ischemic stroke accounting for the majority of cases. Current therapies, including thrombolysis and supportive care, are limited by narrow therapeutic windows, eligibility restrictions, and the brain's limited regenerative capacity, leaving many patients with persistent neurological deficits. Nanotechnology has emerged as a promising strategy to overcome these limitations, offering targeted delivery of therapeutic agents across the blood-brain barrier and modulation of key pathological processes such as oxidative stress and neuroinflammation. Among various nanocarriers, dendrimers, highly branched, nanosized polymers with internal cavities, have demonstrated potential for targeted drug delivery and enhanced neuroprotection in experimental stroke models. This review summarizes the design features, therapeutic applications, and current challenges of dendrimer-based nanocarriers, demonstrating their potential to improve stroke therapy and recovery.
No takes yet. Share an insight, caveat, or question.
Lafi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: